Jean-Marie Cuillerot

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Howard L. Kaufman, Jeffery S. Russell, Omid Hamid et al. · The Lancet Oncology · 2016 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +11

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

Martin Reck, Igor Bondarenko, Alexander Luft et al. · Annals of Oncology · 2012 · 610 citations · Full text

Medicine, Oncology, Pharmacology +11

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

James L. Gulley, Arun Rajan, David R. Spigel et al. · The Lancet Oncology · 2017 · 284 citations · Full text

Medicine, Oncology, Pharmacology +14

T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment

Saskia J. Santegoets, Anita G.M. Stam, Sinéad M. Lougheed et al. · Cancer Immunology Immunotherapy · 2012 · 91 citations · Full text

Medicine, Immunology, Oncology +16

Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).

Thomas J. Lynch, Igor Bondarenko, Alexander Luft et al. · Journal of Clinical Oncology · 2010 · 53 citations

Medicine, Oncology, Pharmacology +17